The demo obtained both its Main endpoints, with semaglutide two.4 mg demonstrating statistically considerable and remarkable advancements in liver fibrosis without having worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH in comparison to placebo.1Contact your heal